FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma By Ogkologos - January 31, 2025 569 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034... June 3, 2026 Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... April 28, 2025 Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests December 21, 2020 Load more HOT NEWS Breast-Cancer Mom Is Living On 84 Pence As She Fights For... Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... How Does Ovarian Cancer Form? A New Study Points to MicroRNA
